« Return to News | Clinical Intelligence

Neurovance receives patent for EB-1020, initiates ADHD trial

Friday, February 22, 2013 01:59 PM

The United States Patent and Trademark Office (USPTO) has issued Neurovance, a Cambridge, Mass.-based company spun out of Euthymics Bioscience, a notice of allowance for a composition of matter patent for EB-1020, providing proprietary protection for EB-1020 through July 2026.

Neurovance also said that it has initiated a phase I clinical trial of EB-1020 with a new sustained-release (SR) formulation to treat adult attention deficit hyperactivity disorder (ADHD).

EB-1020 is being developed to improve efficacy compared to existing non-stimulants, but to do so with less risk of abuse liability and diversion, or non-medicinal use, than the current stimulants (amphetamine and amphetamine-like medications) that are the standard of care in ADHD. This phase I “umbrella” study will evaluate pharmacokinetics, food effects and tolerability of a sustained-release formulation with multiple dose escalation in healthy volunteers. The trial is being conducted on behalf of Neurovance by INC Research and Nucleus Network in Australia. Results are expected during the second quarter, with plans for a phase IIa pilot study in the U.S. later this year.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.